Department of Health Policy and Management, Peking University School of Public Health, Beijing, China.
Brown School, Washington University in St. Louis, St. Louis, Missouri, USA.
BMJ Glob Health. 2023 Jul;8(7). doi: 10.1136/bmjgh-2022-011535.
Since 2019, the Chinese central government has taken significant steps to centralize national purchasing power and has implemented a pooled procurement system. In this paper, we provide an in-depth analysis of China's National Volume-Based Procurement (NVBP) policy, which represents a unique approach to pooled procurement within the pharmaceutical sector. The primary objectives of the NVBP are to reduce drug prices, enhance access to affordable medications, and improve the overall functioning of the pharmaceutical industry in China. Our analysis delves into the key features of the NVBP, including its centralized procurement system, volume-based procurement approach, and the guaranteed procurement volumes allocated to winning bidders. We also address the challenges and implications associated with the NVBP, such as its impact on the pharmaceutical industry, the sustainability of price reductions, and the importance of striking a balance between price reduction and industry sustainability. Through a comparative analysis, we shed light on the distinct characteristics of China's approach to pooled procurement and its potential ramifications for healthcare policies and practices. By examining the NVBP within the broader context of China's evolving healthcare landscape, we aim to contribute to a deeper understanding of the implications and effectiveness of this unique policy initiative.
自 2019 年以来，中国中央政府采取了重大举措集中采购权，并实施了集中采购制度。本文深入分析了中国的国家基于量采购（NVBP）政策，这代表了药品领域集中采购的独特方法。NVBP 的主要目标是降低药品价格，增加负担得起的药物的可及性，并改善中国制药行业的整体运作。我们的分析深入探讨了 NVBP 的关键特点，包括其集中采购系统、基于量的采购方法以及分配给中标者的有保障的采购量。我们还讨论了 NVBP 带来的挑战和影响，例如对制药行业的影响、价格降低的可持续性以及在价格降低和行业可持续性之间取得平衡的重要性。通过比较分析，我们揭示了中国集中采购方法的独特特征及其对医疗保健政策和实践的潜在影响。通过在更广泛的中国不断发展的医疗保健背景下考察 NVBP，我们旨在深入了解这一独特政策倡议的影响和有效性。
